Crown Laboratories, Inc. and Hildred Capital Partners, LLC acquired Bellus Medical.
Bellus’ non-invasive offerings include SkinPen, a medical-grade microneedling device used exclusively by healthcare professionals to improve the appearance of facial acne scars. It is the first micro-referral device to obtain market authorization and market authorization from the FDA or this indication.
Other Belus products include:
- Skinfuse: post-microneedling protocol
- Light: light activated cream
- ProGenTM / RegenLab: plasma systems rich in platelets
Bellus Medical will become the new Aesthetics Division of Crown Laboratories and will be renamed Bellus Aesthetics. Bellus will remain based in Dallas and operate as a wholly-owned subsidiary of Crown Laboratories. Bellus CEO Joe Proctor will become president of Crown’s aesthetic division and join Crown’s board of directors.
“The partnership with Bellus is a truly exciting and significant first step in building our Aesthetics division,” said Jeff Bedard, president and chief executive officer of Crown Laboratories. “Bellus has assembled a truly impressive team with an enviable aesthetic innovation track record, such as SkinPen®, the very first FDA approved microneedling device for the treatment of acne scars. We believe there is a tremendous opportunity for us in aesthetics, and with Bellus as the cornerstone of our new division, we expect to significantly expand our portfolio in the years to come. ”
“We are delighted to have found an irresistible opportunity with a partner to share our vision and approach to growing the business and improving patient outcomes,” said Joe Proctor, Bellus CEO, medical. “The organization is culturally supported State Labs and provides us with the additional resources we need to develop our infrastructure, support future growth and better serve our network of valued suppliers. This represents a unique transaction opportunity to build Bellus into an elite company aesthetic and we look forward to joining our new colleagues and building the Crown aesthetic franchise. ”
“On behalf of Hildred, I am delighted to be working with the Crown on the launch of its new aesthetic division and welcoming Joe and his colleagues to the team,” said David Solomon, Hildred Partner and President of the State Council for Laboratories. “With its unique market position and portfolio, led by the very first class II microneedling device ever recognized, Bellus represents an attractive opportunity for Crown, complements its existing skin care offering and increases its growth potential and consolidation. We will continue to look for distinct and exciting opportunities to build on the consumer health care and prescription product lines of the Crown – and now its line of aesthetic products -. With the launch of the new esta division ”